BMS' neuro renaissance was built on back of Celgene mega-merger

Bristol Myers Squibb's renewed focus on neuroscience is driven by its $74 billion acquisition of Celgene, which provided a strong neuro pipeline including multiple sclerosis and Alzheimer’s disease drug candidates. BMS is advancing treatment options in neuropsychiatric diseases despite past challenges in the field.

This Wire brief sits within Fusion42's coverage of Biotech.